LifeBridge Innovations’ dynamic delivery of TTF will provide the capability to treat cancer in multiple locations in the body simultaneously, allowing us to offer TTF to stage 4 patients who would otherwise be without hope in the absence of a 4th modality. 

In 2012, the World Health Organization reported 14,000,000 new cancer cases and 8,000,000 cancer deaths globally. Everyday in America, more than 1,600 people die from cancer (ACS). These cancer patients do not survive because the present modalities of treatment, surgery, chemotherapy, and radiation eventually fail. At that point, a patient's cancer is recurring and non-responsive. A company called NovoCure offers new hope for cancer victims by introducing tumor treating fields as the 4th modality for treating cancer. This emerging therapy has already been recommended as a standard of care for Glioblastoma patients by the National Comprehensive Cancer Network. However, their static form of delivering TTF is best suited for treating tumors in only one location. LifeBridge Innovations’s dynamic delivery of TTF will provide the capability to treat cancer in multiple locations in body simultaneously, allowing us to offer TTF to stage 4 patients who would otherwise be without hope in the absence of a 4th modality.